Natick investment firm raises $260M for life science companies
Image | Courtesy of ORI Capital
Simone Song, founder and senior partner at ORI Capital and a board member of Affyimmune Therapeutics
ORI Capital, a healthcare-focused investment firm with offices in Natick and Hong Kong, has raised $260 million to support investments into biotechnology companies with the goal of finding treatments for cancer, metabolic disorders, and neurodegenerative diseases.
ORI plans on using these funds to invest in early-stage biotech companies around the world, with a focus on firms working in the areas of diagnostics, drug delivery, and therapeutics for diseases with high mortality rates, according to a press release issued by ORI on Thursday.
ORI was found by Simone Song in 2015. Companies that have received investments from ORI include Semma Therapeutics, a Cambridge-based firm working on a cure for type 1 diabetes, and Pillar Biosciences, a Natick-based company working in diagnostic technology.
“We are in a golden-era of innovation across the intersection of AI and biology, where technological breakthroughs are creating new approaches to diagnosing and treating disease,” Song said in the press release. “We believe the current environment provides an attractive opportunity for investing in the next generation of leading biotech companies.”
ORI shares a Natick office with AffyImmune Therapeutics, a company in ORI’s portfolio that received $30 million from the firm in 2021 for a cancer treatment study. Song is also a board member of AffyImmune.
AffyImmune has 11 local employees and 24 employees company-wide, according to data submitted by the company to the WBJ Research Department.
WBJ Web Partners
Most Recent
Most Recent
0 Comments